 |
Hana Biosciences to Present At the Collins Stewart 4th Annual Growth Conference
Jul 2, 2008
|
6.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., July 2, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced that Steven R. Deitcher, M.D., President & Chief Executive Officer, will present a company update at the Collins Stewart Fourth Annual Growth Conference on Thursday, July ...
|
|
Hana Biosciences Receives U.S. Orphan Drug Designation for Marqibo for the Treatment of Metastatic Uveal Melanoma
Jun 30, 2008
|
11.0 KB |
|
| |
OUTH SAN FRANCISCO, Calif., June 30, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Marqibo® (vincristine sulfate...
|
|
Hana Biosciences to Present Menadione and Alocrest Data At the European Society for Medical Oncology Conference
Jun 23, 2008
|
9.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., June 23, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it will present pre-clinical data on Menadione Topical Lotion and clinical data on Alocrest™ (vinorelbine li...
|
|
Hana Biosciences Receives Notice From Nasdaq
Jun 13, 2008
|
8.7 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., June 13, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it received a letter on June 11, 2008, from the Nasdaq Stock Market, Inc., notifying the company that for the last 30 consecutive business days pri...
|
|
Hana Biosciences Announces Stock Listing Transfer to NASDAQ Capital Market
Jun 4, 2008
|
6.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., June 4, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it received approval from the NASDAQ Listing Qualifications Department to transfer the listing of its common stock from the NASDAQ Global Market to ...
|
|
Hana Biosciences' Phase 2 Clinical Trial of Marqibo for Metastatic Uveal Melanoma Meets Clinical Response Criteria to Advance to Full Enrollment
Jun 2, 2008
|
10.2 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., June 2, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the pre-specified efficacy criteria to proceed to full enrollment of 30 patients has been met in its Phase 2 clinical trial of Marqibo...
|
|
Hana Biosciences Receives Notice From NASDAQ
May 27, 2008
|
6.9 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 27, 2008 (PrimeNewswire via COMTEX News Network) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it received a letter on May 20, 2008, from the Nasdaq Stock Market, Inc., notifying the Company that its total stockholders' ...
|
|
Hana Biosciences Announces First Quarter 2008 Results
May 13, 2008
|
12.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 13, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced financial results for the first quarter ended March 31, 2008.
Net loss was $6.3 million, or $0.19 per share, for the first quarter 2008 compa...
|
|
Hana Biosciences to Present At the Rodman & Renshaw 5th Annual Global Healthcare Conference
May 6, 2008
|
5.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., May 6, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced that Steven R. Deitcher, M.D., President & Chief Executive Officer, will present a company update at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Mon...
|
|
Hana Biosciences Regains NASDAQ Compliance
Apr 29, 2008
|
6.5 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Apr 29, 2008 (PrimeNewswire via COMTEX News Network) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has received notice from the Nasdaq Stock Market that the company has regained compliance with Marketplace Rule 4450(a)(5)...
|
|
Hana Biosciences Announces Conference Call On First Quarter Financial Results and Business Update
Apr 29, 2008
|
5.9 KB |
|
| |
SOUTH SAN FRANCISCO, April 29, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, will announce its 2008 first quarter results on Tuesday, May 13, 2008, after the close of the financial markets.
Following the announcement, Hana Biosciences' mana...
|
|
Hana Biosciences Appoints Anne E. Hagey, M.D., Vice President and Chief Medical Officer
Apr 24, 2008
|
8.3 KB |
|
| |
SOUTH SAN FRANCISCO, April 24, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the appointment of Anne E. Hagey, M.D. as Vice President and Chief Medical Officer. Dr. Hagey will be responsible for all aspects of pre-clinical and clinical ...
|
|
Hana Biosciences Commences Phase 1 Clinical Trial of Topical Menadione for Treatment and/or Prevention of EGFR Inhibitor-Associated Skin Rash
Apr 7, 2008
|
10.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., April 7, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that active cancer patient dosing has commenced in the company's Phase 1 clinical trial of topical menadione lotion for the treatment and/or prevention ...
|
|
Hana Biosciences Announces Fourth Quarter and Year-End 2007 Financial Results
Mar 25, 2008
|
22.6 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 25, 2008 (PRIME NEWSWIRE) -- Hana Biosciences
(Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation
of cancer care, today announced financial results for the fourth quarter and
fiscal year ended December 31, 2007.
Net loss was $3.6 million, or $0.11 pe...
|
|
Hana Biosciences Appoints Paul V. Maier to Board of Directors
Mar 19, 2008
|
8.1 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 19, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the appointment of Paul V. Maier to its Board of Directors. His career has included senior financial leadership positions at Ligand Pharmaceuticals, DF...
|
|
Hana Biosciences Announces Conference Call On Fourth Quarter and Year-End 2007 Financial Results and Business Update
Mar 11, 2008
|
6.0 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 11, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, will announce its 2007 fourth quarter and year-end results on Tuesday, March 25, 2008, after the close of the financial markets.
Following the announcement...
|
|
Hana Biosciences Receives Notice From NASDAQ
Mar 5, 2008
|
7.0 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., March 5, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it received a letter on February 29, 2008, from the Nasdaq Stock Market, Inc., notifying the company that for the last 30 consecutive business days...
|
|
Hana Biosciences Announces New Clinical and Scientific Advisory Board
Feb 27, 2008
|
7.3 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced a reorganization of its Clinical and Scientific Advisory Board (CSAB). The CSAB will provide counsel on clinical and scientific development of the compa...
|
|
Hana Biosciences Announces Top-Line Phase 1 Clinical Trial Data Demonstrating Alocrest to be Well-Tolerated With Promising Anti-Tumor Activity
Feb 12, 2008
|
10.2 KB |
|
| |
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the company has completed patient enrollment in its Phase 1 dose-escalation clinical trial of Alocrest™ (vin...
|
|
Hana Biosciences to Present At the 10th Annual BIO CEO & Investor Conference
Feb 5, 2008
|
5.6 KB |
|
| |
SOUTH SAN FRANCISCO, Feb. 5, 2008 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, announced today that Steven R. Deitcher, M.D., President & Chief Executive Officer, will present a company update at the 10th Annual BIO CEO & Investor Conference on Tuesday, February 12th at...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
Shareholder Briefcase
Printed Materials
Email Alerts
Download Library
RSS News Feeds